Effect of luteinizing hormone-releasing hormone (LHRH) analogue treatment on a cytokine profile in prostate cancer patients

Pharmacological Reports

Volumn 60, Issue 3, 2008, Pages 399-403

  Kaczmarek, Piotr ^a   Pokoca, Lech ^a   Niemirowicz, Jerzy ^b   Majewska, Ewa ^a   Baj, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Ministry of Internal Affairs and Administration Hospital   (Poland)

Author keywords

Cytokines; LHRH analogue; Prostate cancer; Steroid hormones

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GONADORELIN DERIVATIVE; GOSERELIN; INTERLEUKIN 10; INTERLEUKIN 2; PROSTATE SPECIFIC ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

EID: 49349092480     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Batchelor JR, Chapman BA: The influence of sex upon the antibody response to an incompatible tumour. Immunology, 1965, 9, 553-564.
2. Batticane N, Morale MC, Gallo F, Farinella Z, Marchetti B: Luteinizing hormone-releasing hormone signaling at the lymphocyte involves stimulation of interleukin-2 receptor expression. Endocrinology, 1999, 129, 277-286.
3. Becker Y: Molecular immunological approaches to biotherapy of human cancers a review, hypothesis and implications. Anticancer Res, 2006, 26, 1113-1134.
4. Chen H, Jeung E, Stephenson M, Leung PCK: Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor g-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab, 1999, 84, 743-750.
5. Cockshott ID: Clinical pharmacokinetics of goserelin. Clin Pharmacokinet, 2000, 39, 27-48.
6. Damber JE: Endocrine therapy for prostate cancer. Acta Oncol, 2005, 44, 605-609.
7. Filella X, Alcover J, Zarco MA, Beardo P, Molina R, Ballesta AM: Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate, 2000, 44, 271-274.
8. Jacobson JD, Ansari MA: Immunomodulatory actions of gonadal steroids may be mediated by gonadotropin-releasing hormone. Endocrinology, 2004, 145, 330-336.
9. Kawai K, Akaza H: Recent advance in luteinizing hormone-releasing hormone analogue therapy in management of prostate cancer. Nippon Rinsho, 1998, 56, 2108.
10. Kowalczyk E, Krzesiński P, Kura M, Szmigiel B, Błaszczyk J: Anthocyanins in medicin. Pol J Pharmacol, 2003, 699-702.
11. Kundu N, Beaty TL, Jackson MJ, Fulton AM: Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst (Bethesda), 1996, 88, 536-541.
12. Laribi A, Berteau P, Gala JL, Eschwege P, Benoit G, Tombal B, Schmitt F, Loric S: Blood-borne RT-PCR assay for prostasin-specific transcripts to identify circulating prostate cells in cancer patients. Eur Urol, 2001, 39, 65-71.
13. McCann SM, Kimura M, Walczewska A, Karanth S, Rettori V, Yu WH: Hypothalamic control of gonadotropin secretion by LHRH, FSHRF, NO, cytokines, and leptin. Domest Anim Endocrinol, 1998, 15, 333-344.
14. Morale MC, Battícane N, Bartoloni G, Guarcello V, Farinella Z, Galasso MG, Marchetti B: Blockade of central and peripheral luteinizing hormone-releasing hormone (LHRH) receptors in neonatal rats with a potent LHRH-antagonist inhibits the morphollinctional development of the thymus and maturation of the cell-mediated and humoral immune responses. Endocrinology, 1991, 128, 1073-1085.
15. Perambakam SM, Srivastava R, Peace DJ: Distinct cytokine patterns exist in peripheral blood mononuclear cell cultures of patients with prostate cancer. Clin Immunol, 2005, 117, 94-99.
16. Richiter G, Kruger-Krasagakes S, Hein G, Huls C, Schmitt E, Diamantstein T, Blankenstein T: Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res, 1993, 53, 4134-4137.
17. Stearns ME, Rhim J, Wang M: Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res, 1999, 5, 189-196.
18. Tanriverdi F, Silveira LF, MacColl GS, Bouloux PM: The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. J Endocrinol, 2003, 176, 293-304.
19. Veldhuis JD, Urban RJ, Dufau ML: Evidence that androgen negative feedback regulates hypothalamic gonadotropin-releasing hormone impulse strength and the burst-like secretion of biologically active luteinizing hormone in men. J Clin Endocrinol Metab, 1992, 74, 1227-1235.
20. Wise GJ, Marella VK, Talluri G, Shirazian D: Cytokine variations in patients with hormone treated prostate cancer. J Urol, 2000, 164, 722-725.